Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
BackgroundAt present, immunotherapy has become an important treatment for lung cancer. With the widespread use of immune checkpoint inhibitors (ICIs), we must be strict with the emergence of immune related adverse events (irAEs). There are also some patients who do not respond to immunotherapy. Howe...
Main Authors: | Ni Zhao, Ye Yi, Wen Cao, Xiao Fu, Nan Mei, Chunli Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.923531/full |
Similar Items
-
Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-12-01) -
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
by: Hannah Schindler, et al.
Published: (2022-10-01) -
Adverse Events of Oncologic Immunotherapy and Their Management
by: Fedricker Diane Barber
Published: (2019-01-01) -
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
by: Dung-Tsa Chen, et al.
Published: (2023-04-01) -
Rheumatological Adverse Events Following Immunotherapy for Cancer
by: Ioana Cretu, et al.
Published: (2022-01-01)